You are here: Industry Insights > Genentech

News List

Genentech's Tecentriq Shows Promise for First-line Lung Cancer Treatment biospace
March 21, 2018
Genentech, Inc., a Roche Group company, indicated its IMpower131 Phase III clinical trial of Tecentriq with carboplatin and Abraxane met its co-primary endpoint of progression-free survival (PFS) in lung cancer
Bay Area Biotech Company Inked Multi-Year Research Deal with Genentech biospace
December 20, 2017
less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal. The Bay Area company inked a multi-year collaborative agreement with Genentech to discover new small molecules.
Genentech's Tecentriq-Avastin-Chemo Combo Dazzles in Late-Stage Study biospace
December 08, 2017
Genentech Inc. is the result of a third-phase Tecentriq trial announcing positive results from chemotherapy of carboplatin and paclitaxel for previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).
Genentech Dumps Another $650M in New Haven Biotech Arvinas biospace
November 16, 2017
New Haven, Conn.-based Arvinas expanded an ongoing licensing deal with Genentech. The agreement is to develop new drugs using Arvinas’ PROTAC technology. The original deal was inked in October 2015.
FDA accepts Genentech’s sBLA for gazyva to treat untreated follicular lymphoma pharmaceutical-technology
August 30, 2017
The US Food and Drug Administration (FDA) has accepted biotechnology company Genentech’s supplemental biologics licence application (sBLA) and granted priority review for gazyva (obinutuzumab) for the treatment of untreated follicular lymphoma.
FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors August 25, 2017
Genentech announced the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for emicizumab prophylaxis (preventative) as a once-weekly subcutaneous treatment for adults, adoles
Five Prime names ex-Genentech I-O specialist research SVP fiercebiotech
August 21, 2017
Bryan Irving replaces Luis Borges as SVP of research.
FDA grants Genentech’s Alecensa Priority Review cphi-online
August 07, 2017
Designation given for initial treatment of people with ALK-positive lung cancer.
Genentech: Emicizumab Phase III Studies Show Substantial Reduction In Bleeds nasdaq
June 26, 2017
Emicizumab Phase III Studies Show Substantial Reduction In Bleeds
FDA approves Genentech’s Actemra for giant cell arteritis cphi-online
May 25, 2017
Sixth FDA approval for Actemra since its US launch in 2010,

Previous page 1 2 3 4 5 6 7 8 Next page